

Performance in Initiating - Q3: 2018/2019 (1st January 2018 - 31st December 2018)

Research Ethics Committee Reference Number	IRAS number	Name of Trial	Date Site Invited	Date Site Selected	HRA Approval date	Date Site Confirmed by Sponsor	Date Site Confirmed	Non Confirmation Status	Date Site Ready to Start	Date First Patient Recruited	Reasons for delay
17/NS/0018	223787	FUTURE: Female Urgency, Trial of Urodynamics as Routine Evaluation (FUTURE study); a superiority randomised clinical trial to evaluate the effectiveness and cost effectiveness of invasive urodynamic investigations in management of women with refractory overactive bladder symptoms	13/12/2017	12/01/2018	11/08/2017	16/02/2018	19/02/2018	NA	05/03/2018	21/03/2018	None
17/NE/0331	229957	ANACONDA: A Prospective, Global, Multicentre, Real World Outcome Study of Fenestrated Endovascular Aneurysm Repair using the Fenestrated Anaconda device	08/08/2017	23/01/2018	20/12/2017	09/02/2018	12/02/2018	NA	21/02/2018	21/03/2018	None
17/SW/0273	235783	Phase III Randomised, Double-masked, Parallel Group, Multicentre Study to Compare the Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB11 (proposed ranibizumab biosimilar) and Lucentis® in Subjects with Neovascular Age-related Macular Degeneration	28/11/2017	26/01/2018	22/01/2018	12/03/2018	20/03/2018	NA	08/05/2018	14/05/2018	Sponsor: 40 day metric not achieved due to Sponsor delays in budget negotiations. 70 days not met due to delay in permissions impacting on timeframe.
18/EM/0027	235145	A dose-ranging study of intravitreal OPT-302 in combination with ranibizumab, compared with ranibizumab alone, in participants with neovascular age-related macular degeneration (wet AMD)	16/01/2018	16/01/2018	28/02/2018	29/03/2018	05/04/2018	NA	23/05/2018	20/09/2018	Sponsor: 40 day metric not achieved due to Sponsor delays in budget negotiations. 70 days not met due to no eligible patients seen in the time period.

18/LO/0133	228164	MIAMI: Can patients with multiple breast cancers in the same breast avoid mastectomy by having multiple lumpectomies to achieve equivalent rates of local breast cancer recurrence? A randomised controlled feasibility study	20/02/2018	24/05/2018	15/03/2018	07/11/2018	07/11/2018	NA	13/12/2018		Neither NHS (host site) nor sponsor: 40 day metric not achieved due to reliance on other Trusts to provide Radiotherapy QA documentation for approval by the sponsor. Sponsor: 70 day metric not met due to sponsor suspending recruitment to the trial due to the need for an IRMER.
17/WA/0383	233958	WHITE 5: A randomised controlled trial comparing contemporary uncemented hemiarthroplasty with standard-of-care cemented hemiarthroplasty for the treatment of displaced intracapsular hip fractures	09/02/2018	09/02/2018	31/01/2018	14/03/2018	15/03/2018	NA	13/04/2018	03/05/2018	70 days not met due to no eligible patients
17/WA/0242	228068	PULSAR: Prostatic Urethral Lift in Subjects with Acute Urinary Retention Study	17/05/2017	21/03/2018	01/08/2017	19/04/2018	19/04/2018	NA	04/05/2018	26/06/2018	70 days not met due to study teams schedule
16/LO/2143	207415	DAIL - Dietetic Assessment and Intervention in Non Small Cell Lung Cancer	11/10/2017	24/05/2018	01/03/2017	26/06/2018	26/06/2018	NA	03/07/2018	16/11/2018	70 days not met due to staff availability
18/LO/0782	245936	PAN OPTICA - Randomized, Double Masked, Uncontrolled, Multicenter Phase I/II Study to Evaluate Safety and Tolerability of PAN-90806 Eye Drops, Suspension in Treatment-Naïve Participants with Neovascular Age-Related Macular Degeneration (AMD)	16/04/2018	28/06/2018	22/06/2017	27/07/2018	30/07/2018	NA	28/08/2018		
18/EE/0079	237389	APEX 2 - A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel Group Study to evaluate the efficacy and safety of two dose levels of BCX7353 as an oral treatment for the prevention of attacks in subjects with Hereditary Angioedema.	16/02/2018	19/06/2018	18/04/2018	03/07/2018	04/07/2018	NA	09/07/2018	19/07/2018	None
18/SW/0039	229163	BIG BABY - Induction of labour for predicted macrosomia	14/05/2018	18/05/2018	20/03/2018	09/07/2018	11/09/2018	NA	15/10/2018	14/11/2018	NHS Provider - PI availability
16/SS/0137	199347	ATTEST2	12/02/2018	03/08/2018	11/01/2018	06/09/2018	07/09/2018	NA			
17/YH/0392	230501	ROBIN	04/04/2018	10/07/2018	26/01/2018	13/11/2018	20/11/2018	NA			Sponsor - 40 day metric not achieved due to sponsor timelines
18/SC/0371	231957	KESTREL	07/06/2018	23/07/2018	17/08/2018	02/08/2018	23/08/2018	NA	09/10/2018	01/11/2018	None
18/LO/1311	248599	RHINE	07/06/2018	07/09/2018	03/10/2018	04/10/2018	09/10/2018	NA	31/12/2018		
17/SC/0610	227378	ITIND2	13/09/2017	01/08/2018	08/12/2017	06/09/2018	07/09/2018	NA	14/09/2018		

18/SC/0242	238151	BLING III	10/07/2018	18/09/2018	24/08/2018	29/11/2018	07/12/2018	NA			NHS Provider - 40 day metric not achieved due to staff availability
18/EE/0378	248600	PANDA 2	06/06/2018	21/11/2018	09/01/2019			NA			
17/SS/0082	222441	SOSTART	10/09/2018	16/10/2018	05/10/2017	26/11/2018	04/12/2018	NA			Sponsor and NHS Provider - 40 day metric not achieved due to delay in sponsor returning contract to site and staff availability
18/NW/0599	242748	STEPS	14/08/2018	21/11/2018	16/11/2018	14/12/2018	21/12/2018	NA	24/12/2018		